74014-51-0

Basic information

• Product Name: ROKITAMYCIN
• Synonyms: ROKITAMYCIN;3''-Propionylleucomycin A5;Leucomycin V, 4B-butanoate 3B-propanoate (9CI);Ricamycin;TMS 19Q;Leummycin V 4B-bu-tanoate 3 B-propanoate;M-19-Q;Rikamycin
• CAS NO: 74014-51-0
• Molecular Formula: C42H69NO15
• Molecular Weight: 827.99
• Mol File: 74014-51-0.mol
• Article Data: 0

Chemical Properties

• Melting Point: 116°
• Boiling Point: 879.3 °C at 760 mmHg
• Flash Point: 485.6 °C
• Appearance: /
• Density: 1.21 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 13.06±0.70(Predicted)
• CAS DataBase Reference: ROKITAMYCIN(CAS DataBase Reference)
• NIST Chemistry Reference: ROKITAMYCIN(74014-51-0)
• EPA Substance Registry System: ROKITAMYCIN(74014-51-0)

Safety Data

• Hazardous Substances Data: 74014-51-0(Hazardous Substances Data)

Usage

Description

Rokitamycin is a semisynthetic macrolide antibiotic, closely related to miokamycin(2) both in structure and antimicrobial spectrum.

Brand name

RICAMYCIN

Pharmaceutical Applications

3″-Propionyl leucomycin A5. A semisynthetic macrolide. Unstable in acid media. The antibacterial spectrum is identical to that of erythromycin, but it is less active against Gram-positive cocci. It is poorly active against H. influenzae (MIC50 8 mg/L) and Mor. catarrhalis (MIC50 4 mg/L). It displays good activity against Campylobacter spp. (MIC50 0.1 mg/L), L. pneumophila (MIC50 0.1 mg/L) and M. pneumoniae (MIC50 0.003 mg/L). It is active against anaerobes, including some Bacteroides spp. (MIC50 <0.05 mg/L).After a single oral dose of 600 mg, the peak plasma concentration was 1.9 mg/L after 0.6 h. Oral doses of 5, 10 and 15 mg/kg of a syrup formulation given to children achieved plasma concentrations of 0.26, 0.55 and 0.79 mg/L, respectively, after about 40 min. The half-life is around 2 h.It is mainly eliminated in the bile; only about 2% appears in the urine. Its major metabolites are leucomycin A7, 10″-OH-rokitamycin (which show some antibacterial activity) and leucomycin V. In healthy adult volunteers, the proportions of rokitamycin and its metabolites in serum 30 min after a single oral dose of 1200 mg were 18% (leucomycin A7), 33% (10″-OH-rokitamycin) and 9% (leucomycin V). The pharmacokinetic behavior is not altered in patients with liver cirrhosis. It is available in Italy and Japan.

InChI:InChI=1/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1